Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$10.09 -0.04 (-0.39%)
(As of 11/22/2024 ET)

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$9.73
$10.11
50-Day Range
$10.07
$12.30
52-Week Range
$9.15
$13.14
Volume
150,540 shs
Average Volume
170,771 shs
Market Capitalization
$18.26 billion
P/E Ratio
48.05
Dividend Yield
2.97%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Astellas Faces FDA Setback on IZERVAY Application
Astellas Pharma H1 Profit Rises; Lifts FY24 Outlook
Astellas Pharma Withdraws EU Application for Key Drug
Bernstein Releases a Buy Rating on Astellas Pharma (ALPMF)
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $11.90 at the start of the year. Since then, ALPMY stock has decreased by 15.2% and is now trading at $10.09.
View the best growth stocks for 2024 here
.

Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its earnings results on Wednesday, October, 30th. The company reported $0.13 earnings per share for the quarter. The business earned $3.11 billion during the quarter. Astellas Pharma had a trailing twelve-month return on equity of 10.33% and a net margin of 3.26%.

Shares of Astellas Pharma split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
10/30/2024
Today
11/23/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

Net Income
$113 million
Pretax Margin
1.55%

Debt

Sales & Book Value

Annual Sales
$11.11 billion
Cash Flow
$1.16 per share
Book Value
$5.84 per share

Miscellaneous

Outstanding Shares
1,809,663,000
Free Float
N/A
Market Cap
$18.26 billion
Optionable
Not Optionable
Beta
0.36

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners